AI Science Tracker
EN

Multitask neural screening identifies compounds active against Leishmania infantum in vitro

Federal University of Goiás; University of Brasília · 16 Dec 2024 · biology

Discovery

Multitask neural screening identifies compounds active against Leishmania infantum in vitro

Source check: Source checked. Not independent scientific confirmation.

Finding: Multitask neural classification and regression screened approximately 1.3 million purchasable compounds for Leishmania infantum activity. After physicochemical and human structural filtering, 20 selected compounds were tested; nine inhibited promastigotes in vitro. Three had more favorable source-reported selectivity, with LC-15 showing an IC50 of 1.05 µM and selectivity index 30.9. LC-15 was already disclosed in a 2023 antitrypanosomal study; this entry represents the Leishmania result, not a new chemical entity. Intracellular parasite activity, animal efficacy and a proposed proteasome mechanism were not established.

Technology: Multitask deep neural network classification and regression; molecular fingerprints

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Multitask DNN classifiers and regressors transferred information across three Leishmania species to prioritize untested molecules; physicochemical filters, similarity analysis and human inspection then selected 20 for experiments.
Test and result
Twenty model-prioritized, subsequently filtered compounds were evaluated against Leishmania infantum promastigotes. Nine were active; cytotoxicity and selectivity measurements were reported for selected active hits. Three had source-described selectivity indices above 9.
Limitation / still unknown
No intracellular-amastigote efficacy, animal therapeutic efficacy or clinical benefit is established. Six active compounds had less favorable selectivity. LC-15 is the same chemical entity disclosed in the 2023 antitrypanosomal study, whose supplement also reports the same MRC-5 cytotoxicity value; independently new cytotoxicity evidence is not inferred. Its proteasome mechanism remains a hypothesis, and the observed hit rate is not a controlled comparison with conventional screening.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1021/acsomega.4c07994 · https://pmc.ncbi.nlm.nih.gov/articles/PMC11696749/ · https://doi.org/10.4155/fmc-2023-0074 · https://doi.org/10.25402/FMC.24131556.v1 · https://doi.org/10.1021/acsomega.4c07994.s001

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Corrected exact primary DOI/title/PMCID and electronic date; full computational prioritization and result-specific activity/selectivity paragraphs; current PubMed publication-status relationships. Earlier metadata lookup had retrieved a different paper and is not used as evidence. Compared the original 2023 and 2024 author supplements by exact LC-15 chemical name, structure, supplier identifier and NMR evidence; the represented novelty is the Leishmania assay, not chemical-entity novelty..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse biology discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.